{"id":86992,"date":"2023-11-10T09:39:41","date_gmt":"2023-11-10T04:09:41","guid":{"rendered":"http:\/\/finservwealth.com\/astrazeneca-ups-profit-outlook-and-boosts-anti-obesity-pipeline\/"},"modified":"2023-11-10T09:39:41","modified_gmt":"2023-11-10T04:09:41","slug":"astrazeneca-ups-profit-outlook-and-boosts-anti-obesity-pipeline","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/astrazeneca-ups-profit-outlook-and-boosts-anti-obesity-pipeline\/","title":{"rendered":"AstraZeneca ups profit outlook and boosts anti-obesity pipeline"},"content":{"rendered":"<p> The Anglo-Swedish company reported third-quarter profit and revenue just ahead of analyst expectations. For the third consecutive quarter, strong sales of its blockbuster cancer treatments and healthy demand in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy.<\/p><div id=\"finse-1620374483\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/world-news\/astrazeneca-ups-profit-outlookboosts-anti-obesity-pipeline_17319751.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The Anglo-Swedish company reported third-quarter profit and revenue just ahead of analyst expectations. For the third consecutive quarter, strong sales of its blockbuster cancer treatments and healthy demand in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy. The Anglo-Swedish company reported third-quarter profit and revenue just ahead of analyst expectations. For the third consecutive quarter, strong sales of its blockbuster cancer treatments and healthy demand in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/world-news\/astrazeneca-ups-profit-outlookboosts-anti-obesity-pipeline_17319751.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> The Anglo-Swedish company reported third-quarter profit and revenue just ahead of analyst expectations. For the third consecutive quarter, strong sales of its blockbuster cancer treatments and healthy demand in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/world-news\/astrazeneca-ups-profit-outlookboosts-anti-obesity-pipeline_17319751.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The Anglo-Swedish company reported third-quarter profit and revenue just ahead of analyst expectations. For the third consecutive quarter, strong sales of its blockbuster cancer treatments and healthy demand in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy. The Anglo-Swedish company reported third-quarter profit and revenue just ahead of analyst expectations. For the third consecutive quarter, strong sales of its blockbuster cancer treatments and healthy demand in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/world-news\/astrazeneca-ups-profit-outlookboosts-anti-obesity-pipeline_17319751.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> The Anglo-Swedish company reported third-quarter profit and revenue just ahead of analyst expectations. For the third consecutive quarter, strong sales of its blockbuster cancer treatments and healthy demand in emerging markets offset the loss of sales of its COVID-19 vaccine and therapy.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-86992","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2020\/200x200\/A\/AstraZeneca_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/86992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=86992"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/86992\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=86992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=86992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=86992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}